Summary:
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment.
Qualified Participants Must:
• Be between 50 and 85 years of age
•
Have availability of a study partner
•
Have memory loss
Qualified Participants May Receive:
Compensation for time and travel.